The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.

Lung Cancer Clinical Trial

Official title:

A Prospective Observational Study on the Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06019455
• Other study ID #: 2023-FXY-017
• Status: Recruiting
• Start date: June 1, 2022
• Est. completion date: May 30, 2027

Study information

• Verified date: August 2023
• Source: Sun Yat-sen University
• Contact: Bo Qiu
• Phone: +862087343031
• Email: qiubo[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and the association between the level of participation and patients' side effects, quality of life, and long-term survival. Additionally, this study will rate the level of participation from both the patients' and medical staff's perspectives and will compare the differences in ratings from these two viewpoints, as well as their impact on treatment outcomes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: May 30, 2027
• Est. primary completion date: May 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, and esophageal cancer.

2. Planned to undergo definitive chemoradiotherapy ± immunotherapy;

3. Males or females aged 18 to 75;

4. Able to communicate with medical staff. Exclusion Criteria: Patients with cognitive impairments.

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms
• Lung Cancer

Locations

Country	Name	City	State
China	Sun Yat-sen University	Guangzhou

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of >=Grade 3 toxicities	The percentage of patients who develop >=Grade 3 toxicities	2 years
Secondary	Overall survival	2-year survival rate	2 years
Secondary	Progression-free survival	2-year progression-free survival rate	2 years